Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

• Published in: The lancet oncology Vol. 11; no. 3; pp. 266 - 274
• Main Authors: Bartlett, John MS, Prof, Munro, Alison F, MSc, Dunn, Janet A, PhD, McConkey, Christopher, MSc, Jordan, Sarah, MSc, Twelves, Chris J, Prof, Cameron, David A, Prof, Thomas, Jeremy, MBBS, Campbell, Fiona M, MSc, Rea, Daniel W, PhD, Provenzano, Elena, MBBS, Caldas, Carlos, Prof, Pharoah, Paul, BMBCh, Hiller, Louise, PhD, Earl, Helena, MBBS, Poole, Christopher J, Prof
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2010; Elsevier Limited
• Subjects: Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - pharmacology; Antigens, Neoplasm - genetics; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Pharmacological; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Chemotherapy; Chromosomes; Disease-Free Survival; DNA repair; DNA Topoisomerases, Type II - genetics; DNA-Binding Proteins - genetics; Epirubicin - administration & dosage; Epirubicin - pharmacology; Female; Gene Amplification; Genes, erbB-2 - genetics; Hematology, Oncology and Palliative Medicine; Humans; Immunohistochemistry; Kinases; Medical prognosis; Medical research; Middle Aged; Multivariate Analysis; Oligonucleotide Array Sequence Analysis; Patient Selection; Poly-ADP-Ribose Binding Proteins; Predictive Value of Tests; Prospective Studies; Survival Analysis; Tumor Cells, Cultured; Tumors; United Kingdom > UK

Summary Background The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. Metho...